Articles tagged with Melanoma
A study of 12 patients with sinonasal mucosal melanoma found that brisk tumor-infiltrating lymphocytes associated with improved outcomes, while anti-PD-L1 therapy showed potential as a therapeutic strategy. Further research is needed to confirm these findings.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
A mobile app using AI analyzes images of suspected skin lesions and provides guidance on whether they are melanoma or not. The app was tested in primary care and showed promising results, accurately diagnosing melanoma in all cases and determining harmless lesions with a high probability.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
Research by Johns Hopkins Medicine suggests that increased stiffness in aging skin contributes to higher rates of melanoma metastasis by stimulating blood vessel growth and making them leaky. Treating older mice with drugs blocking ICAM1 prevented these changes, shrinking tumors and reducing metastasis.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
A new study found that lockdown-induced delays in diagnosing melanoma led to over 100,000 years of life lost across Europe and £6.1 billion in costs, mainly due to loss of productivity. The research emphasizes the importance of considering unintended side effects in pandemic planning.
Researchers found that tumors with preexisting immune cell networks were most primed to respond to adoptive T cell therapy, and patients whose tumors featured such networks responded best to treatment. The study provides a step towards identifying patients who are likely to benefit from personalized immunotherapies.
A new study found that FDG PET/CT imaging after just one week can predict treatment response in patients with advanced melanoma. The study identified metabolic changes in tumors that corresponded with treatment response and progression-free survival.
A new study estimates that up to 64.6% of melanomas diagnosed in white women and 49.7% in white men were overdiagnosed in 2018, leading to unnecessary treatments. The study found that the lifetime risk of being overdiagnosed with melanoma increased over the years.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
In a new study published in Cancer Research, Moffitt researchers reveal how the antitumor activity of PTEN suppresses cancer-promoting activity through the AKT signaling pathway. PTEN's lipid phosphatase activity inhibits melanoma cell proliferation, invasion, and tumor growth.
Researchers at Moffitt Cancer Center analyzed the mechanisms of action of anti-PD-1/CTLA-4 and anti-PD-1/LAG-3 combination therapies, identifying specific subtypes of CD4 T cells that become activated. The study found differences in how these therapies affect CD4 T cells, leading to distinct anticancer effects.
Moffitt researchers found that HDAC8 inhibition of EP300 leads to melanoma cell metastasis to the brain, while no significant impact on other organs was observed. This study provides evidence for a new therapeutic target to inhibit brain metastasis.
Researchers discovered an alternative immune response involving NK and CD4+ T cells that can recognize and attack cancer cells when the usual recognition marker B2M is missing. This finding holds potential for developing more effective combination cancer immunotherapy treatments.
Scientists developed a synthetic melanin that accelerates wound healing and protects against sun damage. The cream also quiets the immune system, allowing for continuous repair and reducing inflammation.
Researchers at McGill University found that people who use sunscreen are more likely to develop skin cancer due to inadequate application or excessive sun exposure. Sunscreen is not the most effective way to protect against skin cancer, with clothing and avoidance being better options.
A study by Medical University of Vienna found that AI algorithms in smartphone applications perform well in diagnosing pigmented skin lesions, but are outperformed by doctors in treatment decisions. The 7-class algorithm showed equivalent diagnostic accuracy to experts, while the ISIC algorithm performed worse.
Researchers saw a major pathologic response in over half of surgical specimens from patients treated with neoadjuvant pembrolizumab. The treatment shrank over half of advanced melanomas, according to exploratory analyses presented at the European Society of Medical Oncology (ESMO) Congress 2023.
A new AI software has achieved a 100% detection rate for melanoma, significantly improving skin cancer detection accuracy. The software correctly identified 99.5% of all skin cancers and 92.5% of pre-cancerous lesions, with potential to reduce face-to-face consultations and enhance dermatology triage.
A recent study has found that non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma. NMSC accounted for 78% of all skin cancer cases in 2020, resulting in over 63,700 deaths. The study highlights the need to implement effective strategies to reduce fatalities associated with all kinds of skin cancers.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
Researchers from The University of Queensland and The Alfred hospital in Melbourne have identified gene variants associated with a higher risk of nodular melanoma. The study found that four genes with rare DNA variants were linked to the aggressive subtype, which accounts for most melanoma deaths.
Researchers at Dana-Farber and MD Anderson Cancer Center found that MTA buildup in tumor cells impairs T cell function. Depleting MTA with enzymes restores T cell activity, improving checkpoint inhibitor effectiveness in MTAP-deleted cancers.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
UTHSC researchers are studying the role of balanced sex hormones in DNA repair in human melanocytes to determine if hormonal imbalances contribute to melanoma risk. The study aims to find novel prevention methods to decrease melanoma cases and potentially save lives.
Researchers at Moffitt will develop novel targeted alpha-particle therapies for uveal melanoma and other rare melanomas. The grant will fund projects aimed at advancing the therapy's efficacy and personalizing its treatment.
Researchers found decreased in situ and invasive melanoma diagnoses during the pandemic, which may reflect reduced skin cancer screening. Thick melanomas increased primarily due to a decrease in thin melanomas, rather than an absolute increase in thicker ones.
Researchers from Osaka University have identified a novel mechanism by which GREB1 Isoform4 is involved in pyrimidine synthesis and causes malignant melanoma. The study found that GREB1 Is4 promotes cancer cell proliferation and regulates pyrimidine metabolism, suggesting it as a new therapeutic target for melanoma.
A study by McGill University found that higher-income individuals and those with university education had increased rates of melanoma, while those earning less than $50,000 were more likely to work outdoors and experience occupational sun exposure. Men also had higher rates of melanoma and other skin cancers due to increased UV exposure.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Researchers developed a minimally invasive microneedle platform capable of detecting protein biomarkers in response to immunotherapy against melanoma. The approach integrates with ultra-sensitive single-molecule detection and shows promise for effective drug screening and patient stratification.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
Researchers have developed an oncolytic virus that can 'warm up' cold tumors and improve immunotherapy outcomes. The virus was engineered to carry a gene encoding a TGF-β inhibitor, which greatly increased survival rates in mice with aggressive melanoma and other cancers.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
Research found that electrical activity between melanocytes and keratinocytes is critical to melanoma initiation, with GABA signaling playing a key role. The study's findings suggest that molecules carried by vesicles from melanocytes to keratinocytes may trigger the secretion of tumor-promoting proteins.
A new study from the University of South Australia reveals that golfers have a higher lifetime prevalence of skin cancer compared to the general population. The research highlights the importance of sun protection strategies for golfers, who spend extended periods in the sun.
Researchers developed a reinforcement learning model that incorporates human decision-making criteria to improve AI accuracy in skin cancer diagnoses. The study showed increased sensitivity for melanoma and basal cell carcinoma, leading to more accurate diagnoses and optimal treatment decisions.
Researchers have identified podoplanin as a key protein driving the spread of mucosal melanoma, a rare and aggressive form of skin cancer. Eliminating this protein could lead to a potential treatment through antibody therapy, offering hope for patients with this devastating disease.
A recent study found that increased skin cancer screening is not enough to address racial disparities in melanoma survival rates. Researchers suggest that educating physicians about presentation of melanoma in skin of color and making sure people have access to a dermatologist when they have a suspicious lesion could be more effective.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
A phase I trial found that combining fecal transplants with immunotherapy is safe and shows promise in improving clinical responses in 65% of patients. The study used healthy donor microbiome to enhance immune system attack on cancer, offering a new paradigm shift in melanoma treatment.
A new study from Sanford Burnham Prebys identified a protein called NR2F6 that helps melanoma cells evade the immune system, but also promotes anti-tumor immunity when targeted. The researchers hope to develop new drugs that can block this protein's activity, potentially doubling the effectiveness of immunotherapy for melanoma patients.
Scientists found that CXCL13-mediated recruitment of B cells helps predict response to immunotherapy treatment. This cooperation between T cells and B cells is associated with improved survival in patients treated with immunotherapy.
A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A new study reveals that antibody-producing B cells in patients with melanoma may be defective, leading to ineffective responses against the disease. The research finds that active B cells accumulate at the edge of tumors and gather in small groups, carrying specific antibody features that react with T cells and other immune cells.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
Researchers at Karolinska Institutet have identified how memory killer cells are formed and found a correlation between their presence in cancer tissue and improved survival rates in people with melanoma. The study suggests that harnessing the potential of these cells could lead to more effective immunotherapy.
Scientists from Brigham and Women's Hospital have developed a new immuno-therapeutic approach using twin stem cells that can target brain metastatic melanomas. The therapy, which uses an engineered 'twin stem cell model,' activates the immune system to suppress tumor growth and prolong survival in representative preclinical models.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
Researchers at Sanford Burnham Prebys have found a way to revive exhausted T cells, which are crucial for destroying cancerous cells. The new approach targets PSGL-1 protein and slows down T cell exhaustion, significantly reducing tumor growth in mice with immunotherapy-resistant melanoma.
Researchers analyzed genetic changes in organs of recently deceased patients with metastatic cutaneous melanoma to understand how the disease spreads and evolves. They found that cancer cells take advantage of specific organ environments, pointing to the need for distinct treatment approaches.
A new class of immunotherapy has shown promising results in targeting and treating the most aggressive form of skin cancer, malignant melanoma. The study developed an IgE antibody that activates the immune response to fight cancer and slows melanoma growth in mice.
Research suggests that patients with advanced melanoma who receive immunotherapy medications may benefit from maintaining normal vitamin D levels. The study found a favorable response rate in 56% of patients with normal baseline vitamin D levels, compared to 36% with low levels.
A new MYC inhibitor, Omomyc, has shown promising preclinical results in reducing melanoma tumor growth and metastatic capacity by halting the transcription of genes implicated in cell growth and proliferation. The study demonstrates a good prognostic gene signature in melanoma patients with this approach.